Related Experiment Video
Updated: Dec 14, 2025
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant
Melissa E Cullom1, Amanda L Amin2, Christa R Balanoff2
1School of Medicine, University of Kansas, Kansas City, KS, USA.
Background:
The aim of this study was to determine whether differing neoadjuvant chemotherapy (NAC) regimens for HER2 positive breast cancer (HER2+ BC) are associated with differing surgical complications. Our goal was to evaluate postoperative complications in HER2+ BC patients receiving NAC with Herceptin (trastuzumab, H) alone versus in combination with pertuzumab (HP).
Methods:
Retrospective chart review was performed of patients with Stage I-III HER2+ BC receiving NAC from 2007 to 2016. Demographics, tumor characteristics, surgical procedure, and 60-day postoperative complications were analyzed.
Results:
H (n = 101) and HP (n = 132) were similar with respect to tumor characteristics and surgical procedure. Overall operative complications were similar between groups (p = 0.63), as were major versus minor complications (p = 1.0). Subgroup analysis identified a higher rate of complications for lumpectomy patients receiving HP versus H (p = 0.003).
Conclusions:
Neoadjuvant chemotherapy with HP is associated with increased complications after lumpectomy. Additional studies are warranted to assess causative factors for this observation.
More Related Videos
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
